AQST Aquestive Therapeutics Inc

Price (delayed)

$4.15

Market cap

$150.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$207.93M

Sector: Healthcare
Industry: Biotechnology

Highlights

Aquestive Therapeutics's gross margin has increased by 17% YoY and by 3.6% QoQ
Aquestive Therapeutics's quick ratio has decreased by 45% YoY but it has increased by 35% QoQ
The EPS has grown by 36% year-on-year but it has declined by 10% since the previous quarter
The debt has grown by 48% YoY and by 36% from the previous quarter
AQST's equity is down by 33% since the previous quarter

Key stats

What are the main financial stats of AQST
Market
Shares outstanding
36.21M
Market cap
$150.29M
Enterprise value
$207.93M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.54
Earnings
Revenue
$45.85M
EBIT
-$42.76M
EBITDA
-$39.32M
Free cash flow
-$45.98M
Per share
EPS
-$1.66
Free cash flow per share
-$1.37
Book value per share
-$1.44
Revenue per share
$1.36
TBVPS
$1.87
Balance sheet
Total assets
$62.88M
Total liabilities
$111.38M
Debt
$89.45M
Equity
-$48.5M
Working capital
$23.52M
Liquidity
Debt to equity
-1.84
Current ratio
2.11
Quick ratio
1.84
Net debt/EBITDA
-1.47
Margins
EBITDA margin
-85.8%
Gross margin
71.7%
Net margin
-121.7%
Operating margin
-93.6%
Efficiency
Return on assets
-92.5%
Return on equity
N/A
Return on invested capital
-51.5%
Return on capital employed
-102.3%
Return on sales
-93.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AQST stock price

How has the Aquestive Therapeutics stock price performed over time
Intraday
-2.12%
1 week
-4.38%
1 month
-19.73%
1 year
14.33%
YTD
-22.43%
QTD
-20.19%

Financial performance

How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$45.85M
Gross profit
$32.89M
Operating income
-$42.89M
Net income
-$55.78M
Gross margin
71.7%
Net margin
-121.7%
The net margin has contracted by 40% from the previous quarter but it has grown by 3.3% YoY
Aquestive Therapeutics's operating margin has decreased by 39% QoQ but it has increased by 6% YoY
The operating income has increased by 19% YoY but it has decreased by 15% from the previous quarter
Aquestive Therapeutics's revenue has decreased by 17% from the previous quarter and by 13% YoY

Growth

What is Aquestive Therapeutics's growth rate over time

Valuation

What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.54
The EPS has grown by 36% year-on-year but it has declined by 10% since the previous quarter
AQST's equity is down by 33% since the previous quarter
Aquestive Therapeutics's revenue has decreased by 17% from the previous quarter and by 13% YoY
AQST's P/S is 11% above its last 4 quarters average of 2.8

Efficiency

How efficient is Aquestive Therapeutics business performance
The company's return on invested capital rose by 47% YoY but it fell by 6% QoQ
The return on sales has declined by 39% since the previous quarter but it has grown by 14% year-on-year
AQST's ROA is down by 24% since the previous quarter but it is up by 14% year-on-year

Dividends

What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AQST.

Financial health

How did Aquestive Therapeutics financials performed over time
The company's total assets is 44% lower than its total liabilities
Aquestive Therapeutics's quick ratio has decreased by 45% YoY but it has increased by 35% QoQ
The current ratio has declined by 43% year-on-year but it has increased by 23% since the previous quarter
AQST's debt to equity has surged by 81% year-on-year but it is down by 2.2% since the previous quarter
The debt has grown by 48% YoY and by 36% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.